Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.
about
Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemiaMyeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant CyclophosphamideComparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched TransplantationInterpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donorsAlternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allChallenges in treating older patients with acute myeloid leukemia.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrPharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesOnce daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsStem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and muImpact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patientsViewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)The evolution of hematopoietic SCT in myelodysplastic syndrome.Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR
P2860
Q26744283-20A82F25-B473-4C42-B296-00D245719292Q26767438-CDD87301-9A67-4C86-8ACA-5CAC4B5341D2Q26771749-ACFC0EBB-0617-4FE0-9698-99CF3A29CCBFQ30884173-0F3263F1-5B92-4950-9AAF-6FFB489FFAABQ33737884-E4C3CA43-52B5-4396-81B9-CD8611765581Q33747297-C631AA84-D4EA-4F72-9C25-1086043B8D3BQ33859061-8643C642-302C-4928-9CB1-CD511F9AA5D8Q33886217-BE914B24-06C7-40C0-93D6-BAA575FAFA0FQ33917170-EFD534F9-DBBE-4D36-9040-FA738B6EEC9CQ33985549-B9CDF6DE-93ED-46CD-B103-2F5F730BA238Q33990856-1521CC9E-40D1-42B3-8BEA-285F67E9C8EAQ34044024-39C4959A-2657-42AA-928D-D53005C93F3BQ34220717-1BFFE839-F566-4E5A-A5C3-F998C217FC4AQ34360641-FA98610B-DCFE-4716-A092-D51CEA40EB96Q34463645-36EE1F7A-7504-44B4-9403-76065699A8C7Q34505185-96548AB5-6F90-4D0D-8799-2E58F2E82DD1Q34572795-8FB475D6-5928-45EC-A790-A36EE1C3AFB7Q34630588-9BBC5523-5827-4C6E-8F00-7F2B73BD80C7Q34664111-063EE76E-4176-4D1A-B4BF-65E7EB72245EQ34667853-D8D4667C-EACC-4973-9BBA-B01DABB3DB94Q35136616-E6917F0F-B90C-4EDE-B30D-5E9CAA4D3C08Q35193735-11D320D2-D9FB-47FC-A764-3D11927CB7CBQ35800814-2F68CF8D-EEA2-427D-B1E4-B2D2B2C78914Q35838113-3C0080A3-70A0-40F0-A2EB-BE1263D8BE25Q36548362-6E50EB1D-0A2B-4C36-A90A-8C231EF25C58Q36570651-17418D65-FEA0-4FAC-802F-2815E9DF0372Q36608468-D83E804C-B06D-4C14-8E72-04D3FA18E0DDQ36687119-D45A1BED-CB9E-4259-BBDE-8C8273B2AA52Q36742108-7141625E-4014-436E-B526-036DB5395016Q36824553-6ED9C268-5A56-4D41-A615-507B5BAE57CEQ36951734-9F720FA5-C544-4DAA-8E40-976996FCFE08Q37081469-B5AFA7F5-9CB7-4B93-A36F-4289045D7AE9Q37140698-F8F9A240-4CC4-4001-9EAF-D648843F6EE2Q37159533-5B8A8940-31E4-4FE0-B880-B7FE67EB2369Q37286248-4CBE0D9B-0695-4324-A2B7-9200AE04442AQ37337422-68CE5039-1901-491C-9E71-3533FCD39F87Q37380958-2DCC5405-205A-48AC-A6B4-1554B6A3AE70Q37404489-B4FBA893-6B76-4E42-B40F-CAD946AE94DAQ37419348-FFAD03A7-3A07-4662-938E-E67B6AB637FFQ37490480-91D17F23-6A81-4460-8615-B8E6AD3253A1
P2860
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Allogeneic hematopoietic stem- ...... g: the role of dose intensity.
@en
Allogeneic hematopoietic stem- ...... g: the role of dose intensity.
@nl
type
label
Allogeneic hematopoietic stem- ...... g: the role of dose intensity.
@en
Allogeneic hematopoietic stem- ...... g: the role of dose intensity.
@nl
prefLabel
Allogeneic hematopoietic stem- ...... g: the role of dose intensity.
@en
Allogeneic hematopoietic stem- ...... g: the role of dose intensity.
@nl
P2093
P2860
P356
P1433
P1476
Allogeneic hematopoietic stem- ...... g: the role of dose intensity.
@en
P2093
Ben-Bassat I
Shem-Tov N
Yerushalmi R
Yeshurun M
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404037
P577
2006-02-01T00:00:00Z